Key Highlights

  • EVE shares traded at $0.013, up 18.18%, during the 27 October 2026 trading session.
  • Pilot dosing for Libbo is now expected in Q4 2026, with data in early 2027.
  • Apixaban solubility exceeded 50 mg/mL, against a baseline of about 0.6 mg/mL.

Shares in EVE Health Group Ltd (ASX:EVE) were trading at $0.013, up 18.18%, during the 27 October 2026 trading session, while the S&P/ASX 200 index was at 8,817.80, up 0.090% (7.90 points), at 12:36 pm GMT+11. EVE Health Group is an Australian life sciences company developing reformulated medicines, including the oral soluble film Libbo. The company’s most recent update in the materials reviewed is its June 2026 quarterly update, dated 31 July 2026.

Libbo Pilot Study (31 July 2026)

In its update dated 31 July 2026, EVE said the protocol for the pilot study of Libbo, a 10 mg vardenafil oral soluble film for erectile dysfunction, was finalised and a contract research organisation and clinical site engaged. The study compares Libbo with an approved vardenafil reference product in healthy male participants.

Dosing is now expected in Q4 2026 with data in early 2027, a change to the timing in a 16 June 2026 announcement. The company said it has confirmed regulatory steps needed before dosing and that there are no safety, efficacy or formulation issues affecting the program.

Apixaban Solubilisation

Testing showed apixaban, the active ingredient in the anticoagulant Eliquis, reached solubility above 50 mg/mL using EVE’s proprietary technology, against a baseline aqueous solubility of about 0.6 mg/mL. The company said the result supports its reformulation program.

Leadership

Ben Rohr was appointed Chief Executive Officer, which the company said is intended to sharpen its focus on commercial execution.

Pipeline and Corporate Background

Ben Rohr became Chief Executive Officer effective 27 April 2026, having previously served as Chief Operating Officer and led the integration of the Nextract acquisition. Subject to satisfactory pilot results, EVE intends to advance Libbo into a pivotal bioequivalence study to support registration on the Australian Register of Therapeutic Goods. The company also intends to progress reformulation programs in premature ejaculation, combination erectile dysfunction and premature ejaculation therapy, and anticoagulation. A provisional patent application has been lodged for the apixaban work, and EVE follows a capital-light, partner-led model, assessing licensing and supply opportunities with pharmaceutical partners.

Sector Context

The broader market provides the backdrop for the session. The S&P/ASX 200 index was at 8,817.80, up 0.090% (7.90 points), at 12:36 pm GMT+11. Reformulation developers in life sciences generally progress through bioequivalence studies against reference products before regulatory submissions.

What to Watch Ahead

The update points to pilot dosing in the fourth quarter of 2026, pilot data in early 2027 and a subsequent pivotal bioequivalence study.

Risks

The pilot timetable was moved from the original plan, and the study results will inform a later pivotal study. The update is dated 31 July 2026.

Closing View

EVE shares rose during the session at a low share price. The latest available company update describes a clinical timetable that extends into 2027.